1
|
Leow JWH, Chan ECY. CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control. Pharmacol Ther 2024; 258:108637. [PMID: 38521247 DOI: 10.1016/j.pharmthera.2024.108637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2023] [Revised: 02/06/2024] [Accepted: 03/11/2024] [Indexed: 03/25/2024]
Abstract
Cytochrome P450 2 J2 (CYP2J2) is primarily expressed extrahepatically and is the predominant epoxygenase in human cardiac tissues. This highlights its key role in the metabolism of endogenous substrates. Significant scientific interest lies in cardiac CYP2J2 metabolism of arachidonic acid (AA), an omega-6 polyunsaturated fatty acid, to regioisomeric bioactive epoxyeicosatrienoic acid (EET) metabolites that show cardioprotective effects including regulation of cardiac electrophysiology. From an in vitro perspective, the accurate characterization of the kinetics of CYP2J2 metabolism of AA including its inhibition and inactivation by drugs could be useful in facilitating in vitro-in vivo extrapolations to predict drug-AA interactions in drug discovery and development. In this review, background information on the structure, regulation and expression of CYP2J2 in human heart is presented alongside AA and EETs as its endogenous substrate and metabolites. The in vitro and in vivo implications of the kinetics of this endogenous metabolic pathway as well as its perturbation via inhibition and inactivation by drugs are elaborated. Additionally, the role of CYP2J2-mediated metabolism of AA to EETs in cardiac electrophysiology will be expounded.
Collapse
Affiliation(s)
- Jacqueline Wen Hui Leow
- Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
| | - Eric Chun Yong Chan
- Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore.
| |
Collapse
|
2
|
Wiley AM, Yang J, Madhani R, Nath A, Totah RA. Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review. Drug Metab Rev 2024; 56:145-163. [PMID: 38478383 DOI: 10.1080/03602532.2024.2329928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Accepted: 03/06/2024] [Indexed: 03/21/2024]
Abstract
Drug withdrawal post-marketing due to cardiotoxicity is a major concern for drug developers, regulatory agencies, and patients. One common mechanism of cardiotoxicity is through inhibition of cardiac ion channels, leading to prolongation of the QT interval and sometimes fatal arrythmias. Recently, oxylipin signaling compounds have been shown to bind to and alter ion channel function, and disruption in their cardiac levels may contribute to QT prolongation. Cytochrome P450 2J2 (CYP2J2) is the predominant CYP isoform expressed in cardiomyocytes, where it oxidizes arachidonic acid to cardioprotective epoxyeicosatrienoic acids (EETs). In addition to roles in vasodilation and angiogenesis, EETs bind to and activate various ion channels. CYP2J2 inhibition can lower EET levels and decrease their ability to preserve cardiac rhythm. In this review, we investigated the ability of known CYP inhibitors to cause QT prolongation using Certara's Drug Interaction Database. We discovered that among the multiple CYP isozymes, CYP2J2 inhibitors were more likely to also be QT-prolonging drugs (by approximately 2-fold). We explored potential binding interactions between these inhibitors and CYP2J2 using molecular docking and identified four amino acid residues (Phe61, Ala223, Asn231, and Leu402) predicted to interact with QT-prolonging drugs. The four residues are located near the opening of egress channel 2, highlighting the potential importance of this channel in CYP2J2 binding and inhibition. These findings suggest that if a drug inhibits CYP2J2 and interacts with one of these four residues, then it may have a higher risk of QT prolongation and more preclinical studies are warranted to assess cardiovascular safety.
Collapse
Affiliation(s)
- Alexandra M Wiley
- Department of Medicinal Chemistry, University of WA School of Pharmacy, Seattle, WA, USA
| | - Jade Yang
- Department of Medicinal Chemistry, University of WA School of Pharmacy, Seattle, WA, USA
| | - Rivcka Madhani
- Department of Medicinal Chemistry, University of WA School of Pharmacy, Seattle, WA, USA
| | - Abhinav Nath
- Department of Medicinal Chemistry, University of WA School of Pharmacy, Seattle, WA, USA
| | - Rheem A Totah
- Department of Medicinal Chemistry, University of WA School of Pharmacy, Seattle, WA, USA
| |
Collapse
|
3
|
Abstract
INTRODUCTION Cytochrome P450s (CYPs) are a superfamily of monooxygenases with diverse biological roles. CYP2J2 is an isozyme highly expressed in the heart where it metabolizes endogenous substrates such as N-3/N-6 polyunsaturated fatty acids (PUFA) to produce lipid mediators involved in homeostasis and cardioprotective responses. Expanding our knowledge of the role CYP2J2 has within the heart is important for understanding its impact on cardiac health and disease. AREAS COVERED The objective of this review was to assess the state of knowledge regarding cardiac CYP2J2. A literature search was conducted using PubMed-MEDLINE (from 2022 and earlier) to evaluate relevant studies regarding CYP2J2 mediated cardioprotection, small molecule modulators, effects of CYP2J2 substrates toward biologically relevant effects and implications of CYP2J2 polymorphisms and sexual dimorphism in the heart. EXPERT OPINION Cardiac CYP2J2-mediated metabolism of endogenous and exogenous substrates have been shown to impact cardiac function. Identifying individual factors, like sex and age, that affect CYP2J2 require further elucidation to better understand CYP2J2's clinical relevance. Resolving the biological targets and activities of CYP2J2-derived PUFA metabolites will be necessary to safely target CYP2J2 and design novel analogues. Targeting CYP2J2 for therapeutic aims offers a potential novel approach to regulating cardiac homeostasis, drug metabolism and cardioprotection.
Collapse
|
4
|
Li L, Liu R, Peng C, Chen X, Li J. Pharmacogenomics for the efficacy and side effects of antihistamines. Exp Dermatol 2022; 31:993-1004. [PMID: 35538735 DOI: 10.1111/exd.14602] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 05/01/2022] [Accepted: 05/09/2022] [Indexed: 11/27/2022]
Abstract
Antihistamines, especially H1 antihistamines, are widely used in the treatment of allergic diseases such as urticaria and allergic rhinitis, mainly for reversing elevated histamine and anti-allergic effects. Antihistamines are generally safe, but some patients experience adverse reactions, such as cardiotoxicity, central inhibition, and anticholinergic effects. There are also individual differences in antihistamine efficacy in clinical practice. The concept of individualized medicine has been deeply rooted in people's minds since it was put forward. Pharmacogenomics is the study of the role of inheritance in individual variations in drug response. In recent decades, pharmacogenomics has been developing rapidly, which provides new ideas for individualized medicine. Polymorphisms in the genes encoding metabolic enzymes, transporters, and target receptors have been shown to affect the efficacy of antihistamines. In addition, recent evidence suggests that gene polymorphisms influence urticaria susceptibility and antihistamine therapy. Here, we summarize current reports in this area, aiming to contribute to future research in antihistamines and clinical guidance for antihistamines use in individualized medicine.
Collapse
Affiliation(s)
- Liqiao Li
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.,Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Runqiu Liu
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.,Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Cong Peng
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.,Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Xiang Chen
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.,Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Jie Li
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.,Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
| |
Collapse
|
5
|
Das A, Weigle AT, Arnold WR, Kim JS, Carnevale LN, Huff HC. CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design. Pharmacol Ther 2020; 215:107601. [PMID: 32534953 PMCID: PMC7773148 DOI: 10.1016/j.pharmthera.2020.107601] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Accepted: 05/28/2020] [Indexed: 12/11/2022]
Abstract
Cytochrome P450 (CYP) epoxygenases are a special subset of heme-containing CYP enzymes capable of performing the epoxidation of polyunsaturated fatty acids (PUFA) and the metabolism of xenobiotics. This dual functionality positions epoxygenases along a metabolic crossroad. Therefore, structure-function studies are critical for understanding their role in bioactive oxy-lipid synthesis, drug-PUFA interactions, and for designing therapeutics that directly target the epoxygenases. To better exploit CYP epoxygenases as therapeutic targets, there is a need for improved understanding of epoxygenase structure-function. Of the characterized epoxygenases, human CYP2J2 stands out as a potential target because of its role in cardiovascular physiology. In this review, the early research on the discovery and activity of epoxygenases is contextualized to more recent advances in CYP epoxygenase enzymology with respect to PUFA and drug metabolism. Additionally, this review employs CYP2J2 epoxygenase as a model system to highlight both the seminal works and recent advances in epoxygenase enzymology. Herein we cover CYP2J2's interactions with PUFAs and xenobiotics, its tissue-specific physiological roles in diseased states, and its structural features that enable epoxygenase function. Additionally, the enumeration of research on CYP2J2 identifies the future needs for the molecular characterization of CYP2J2 to enable a new axis of therapeutic design.
Collapse
Affiliation(s)
- Aditi Das
- Department of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA; Department of Biochemistry, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA; Division of Nutritional Sciences, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA; Center for Biophysics and Computational Biology, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA; Department of Bioengineering, Neuroscience Program, Beckman Institute for Advanced Science and Technology, Cancer Center at Illinois, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA.
| | - Austin T Weigle
- Department of Chemistry, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA
| | - William R Arnold
- Department of Biochemistry, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA
| | - Justin S Kim
- Division of Nutritional Sciences, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA
| | - Lauren N Carnevale
- Department of Biochemistry, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA
| | - Hannah C Huff
- Department of Chemistry, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA
| |
Collapse
|
6
|
Sisignano M, Steinhilber D, Parnham MJ, Geisslinger G. Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications. Drug Discov Today 2020; 25:1744-1753. [DOI: 10.1016/j.drudis.2020.07.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2020] [Revised: 06/16/2020] [Accepted: 07/02/2020] [Indexed: 12/30/2022]
|
7
|
Zhang Y. Computational Investigations of Heme Carbenes and Heme Carbene Transfer Reactions. Chemistry 2019; 25:13231-13247. [DOI: 10.1002/chem.201901984] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 06/19/2019] [Indexed: 12/15/2022]
Affiliation(s)
- Yong Zhang
- Department of Chemistry and Chemical Biology Stevens Institute of Technology 1 Castle Point on Hudson Hoboken NJ 07030 USA
| |
Collapse
|
8
|
Ikemura N, Yamaori S, Kobayashi C, Kamijo S, Murayama N, Yamazaki H, Ohmori S. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact 2019; 306:1-9. [DOI: 10.1016/j.cbi.2019.04.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2019] [Revised: 03/25/2019] [Accepted: 04/02/2019] [Indexed: 12/24/2022]
|
9
|
Lafite P, André F, Graves JP, Zeldin DC, Dansette PM, Mansuy D. Role of Arginine 117 in Substrate Recognition by Human Cytochrome P450 2J2. Int J Mol Sci 2018; 19:ijms19072066. [PMID: 30012976 PMCID: PMC6073854 DOI: 10.3390/ijms19072066] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 07/06/2018] [Accepted: 07/13/2018] [Indexed: 01/10/2023] Open
Abstract
The influence of Arginine 117 of human cytochrome P450 2J2 in the recognition of ebastine and a series of terfenadone derivatives was studied by site-directed mutagenesis. R117K, R117E, and R117L mutants were produced, and the behavior of these mutants in the hydroxylation of ebastine and terfenadone derivatives was compared to that of wild-type CYP2J2. The data clearly showed the importance of the formation of a hydrogen bond between R117 and the keto group of these substrates. The data were interpreted on the basis of 3D homology models of the mutants and of dynamic docking of the substrates in their active site. These modeling studies also suggested the existence of a R117-E222 salt bridge between helices B’ and F that would be important for maintaining the overall folding of CYP2J2.
Collapse
Affiliation(s)
- Pierre Lafite
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CNRS UMR8601, Université Paris Descartes, 75270 Paris CEDEX 06, France.
| | - François André
- Institute for Integrative Biology of the Cell (I2BC), DRF/Joliot/SB2SM, CEA, CNRS, Université Paris-Saclay, F-91198 Gif-sur-Yvette CEDEX, France.
| | - Joan P Graves
- Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.
| | - Darryl C Zeldin
- Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.
| | - Patrick M Dansette
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CNRS UMR8601, Université Paris Descartes, 75270 Paris CEDEX 06, France.
| | - Daniel Mansuy
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CNRS UMR8601, Université Paris Descartes, 75270 Paris CEDEX 06, France.
| |
Collapse
|
10
|
Solanki M, Pointon A, Jones B, Herbert K. Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity. Drug Metab Dispos 2018; 46:1053-1065. [DOI: 10.1124/dmd.117.078964] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Accepted: 04/19/2018] [Indexed: 12/11/2022] Open
|
11
|
Jeong D, Park HG, Lim YR, Lee Y, Kim V, Cho MA, Kim D. Terfenadine metabolism of human cytochrome P450 2J2 containing genetic variations (G312R, P351L and P115L). Drug Metab Pharmacokinet 2017; 33:61-66. [PMID: 29223463 DOI: 10.1016/j.dmpk.2017.10.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 09/22/2017] [Accepted: 10/30/2017] [Indexed: 12/22/2022]
Abstract
The human cytochrome P450 2J2 is involved in several metabolic reactions, including the oxidation of important therapeutics and epoxidation of endogenous arachidonic acid. At least ten genetic variations of P450 2J2 have been identified, but their effects on enzymatic activity have not been clearly characterized. Here, we evaluated the functional effects of three genetic variations of P450 2J2 (G312R, P351L, and P115L). Recombinant enzymes of wild-type and three variant P450 2J2 were heterologously expressed in Escherichia coli and purified. P450 expression levels in the wild-type and two variants (P351L and P115L) were 142-231 nmol per liter culture, while the G312R variant showed no holoenzyme peak in the CO-binding spectra. Substrate binding titrations to terfenadine showed that the wild-type and two variants displayed Kd values of 0.90-2.2 μM, indicating tight substrate binding affinities. Steady-state kinetic analysis for t-butyl methyl hydroxylation of terfenadine indicated that two variant enzymes had similar kcat and Km values to wild-type P450 2J2. The locations of mutations in three-dimensional structural models indicated that the G312R is located in the I-helix region near the formal active site in P450 2J2 and its amino acid change affected the structural stability of the P450 heme environment.
Collapse
Affiliation(s)
- Dabin Jeong
- Department of Biological Sciences, Konkuk University, Seoul, 05025, South Korea
| | - Hyoung-Goo Park
- Department of Biological Sciences, Konkuk University, Seoul, 05025, South Korea
| | - Young-Ran Lim
- Department of Biological Sciences, Konkuk University, Seoul, 05025, South Korea
| | - Yejin Lee
- Department of Biological Sciences, Konkuk University, Seoul, 05025, South Korea
| | - Vitchan Kim
- Department of Biological Sciences, Konkuk University, Seoul, 05025, South Korea
| | - Myung-A Cho
- Department of Biological Sciences, Konkuk University, Seoul, 05025, South Korea
| | - Donghak Kim
- Department of Biological Sciences, Konkuk University, Seoul, 05025, South Korea.
| |
Collapse
|
12
|
Lin HL, Zhang H, Walker VJ, D'Agostino J, Hollenberg PF. Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds. Drug Metab Dispos 2017; 45:990-999. [PMID: 28698302 DOI: 10.1124/dmd.117.075846] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 07/06/2017] [Indexed: 12/18/2022] Open
Abstract
The mechanism-based inactivation of human CYP2J2 by three terminal acetylenic compounds: N-(methylsulfonyl)-6-(2-propargyloxyphenyl)hexanamide (MS), 17-octadecynoic acid (OD), and danazol (DZ) was investigated. The loss of hydroxyebastine (OHEB) carboxylation activity in a reconstituted system was time- and concentration-dependent and required NADPH for MS and OD, but not DZ. The kinetic constants for the mechanism-based inactivation of OHEB carboxylation activity were: KI of 6.1 μM and kinact of 0.22 min-1 for MS and KI of 2.5 μM and kinact of 0.05 min-1 for OD. The partition ratios for MS and OD were ∼10 and ∼20, respectively. Inactivation of CYP2J2 by MS or OD resulted in a loss of the native heme spectrum and a similar decrease in the reduced CO difference spectrum. A heme adduct was observed in the MS-inactivated CYP2J2. The possible reactive metabolite which covalently modified the prosthetic heme was characterized by analysis of the glutathione conjugates formed by MS or OD following oxygenation of the ethynyl moiety. Liquid chromatography-mass spectrometry showed that inactivation by MS or OD did not lead to modification of apoprotein. Interaction of CYP2J2 with DZ produced a type II binding spectrum with a Ks of 2.8 μM and the IC50 for loss of OHEB carboxylation activity was 0.18 μM. In conclusion, heme modification by MS and OD was responsible for the mechanism-based inactivation of CYP2J2. The results suggest that the ethynyl moiety of MS and OD faces the heme iron, whereas the isoxazole ring of DZ is preferentially oriented toward the heme iron of CYP2J2.
Collapse
Affiliation(s)
- Hsia-Lien Lin
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan
| | - Haoming Zhang
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan
| | - Vyvyca J Walker
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan
| | - Jaime D'Agostino
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan
| | - Paul F Hollenberg
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan
| |
Collapse
|
13
|
Dhers L, Ducassou L, Boucher JL, Mansuy D. Cytochrome P450 2U1, a very peculiar member of the human P450s family. Cell Mol Life Sci 2017; 74:1859-1869. [PMID: 28083596 PMCID: PMC11107762 DOI: 10.1007/s00018-016-2443-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 12/15/2016] [Accepted: 12/16/2016] [Indexed: 12/14/2022]
Abstract
Cytochrome P450 2U1 (CYP2U1) exhibits several distinctive characteristics among the 57 human CYPs, such as its presence in almost all living organisms with a highly conserved sequence, its particular gene organization with only five exons, its major location in thymus and brain, and its protein sequence involving an unusually long N-terminal region containing 8 proline residues and an insert of about 20 amino acids containing 5 arginine residues after the transmembrane helix. Few substrates, including fatty acids, N-arachidonoylserotonin (AS), and some drugs, have been reported so far. However, its biological roles remain largely unknown, even though CYP2U1 mutations have been involved in some pathological situations, such as complicated forms of hereditary spastic paraplegia. These data together with its ability to hydroxylate some fatty acids and AS suggest its possible role in lipid metabolism.
Collapse
Affiliation(s)
- L Dhers
- UMR 8601 CNRS, Université Paris Descartes, Paris Sorbonne Cité, 45 rue des Saints Pères, 75006, Paris, France
| | - L Ducassou
- UMR 8601 CNRS, Université Paris Descartes, Paris Sorbonne Cité, 45 rue des Saints Pères, 75006, Paris, France
| | - J-L Boucher
- UMR 8601 CNRS, Université Paris Descartes, Paris Sorbonne Cité, 45 rue des Saints Pères, 75006, Paris, France.
| | - D Mansuy
- UMR 8601 CNRS, Université Paris Descartes, Paris Sorbonne Cité, 45 rue des Saints Pères, 75006, Paris, France
| |
Collapse
|
14
|
Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy. Biochem Pharmacol 2017; 135:12-21. [PMID: 28237650 DOI: 10.1016/j.bcp.2017.02.017] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Accepted: 02/21/2017] [Indexed: 12/15/2022]
Abstract
Extrahepatic cytochrome P450 enzymes (CYP450) are pivotal in the metabolism of endogenous substrates and xenobiotics. CYP2J2 is a major cardiac CYP450 and primarily metabolizes polyunsaturated fatty acids such as arachidonic acid to cardioactive epoxyeicosatrienoic acids. Due to its role in endobiotic metabolism, CYP2J2 has been actively studied in recent years with the focus on its biological functions in cardiac pathophysiology. Additionally, CYP2J2 metabolizes a number of xenobiotics such as astemizole and terfenadine and is potently inhibited by danazol and telmisartan. Notably, CYP2J2 is found to be upregulated in multiple cancers. Hence a number of specific CYP2J2 inhibitors have been developed and their efficacy in inhibiting tumor progression has been actively studied. CYP2J2 inhibitor such as C26 (1-[4-(vinyl)phenyl]-4-[4-(diphenyl-hydroxymethyl)-piperidinyl]-butanone hydrochloride) caused marked reduction in tumor proliferation and migration as well as promoted apoptosis in cancer cells. In this review, we discuss the role of CYP2J2 in cardiac pathophysiology and cancer therapeutics. Additionally, we provide an update on the substrates, reversible inhibitors and irreversible inhibitors of CYP2J2. Finally, we discuss the current gaps and future directions in CYP2J2 research.
Collapse
|
15
|
Dhers L, Pietrancosta N, Ducassou L, Ramassamy B, Dairou J, Jaouen M, André F, Mansuy D, Boucher JL. Spectral and 3D model studies of the interaction of orphan human cytochrome P450 2U1 with substrates and ligands. Biochim Biophys Acta Gen Subj 2017; 1861:3144-3153. [DOI: 10.1016/j.bbagen.2016.07.018] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Revised: 07/06/2016] [Accepted: 07/21/2016] [Indexed: 02/08/2023]
|
16
|
Computational modelling of the binding of arachidonic acid to the human monooxygenase CYP2J2. J Mol Model 2016; 22:279. [DOI: 10.1007/s00894-016-3134-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2016] [Accepted: 10/09/2016] [Indexed: 01/08/2023]
|
17
|
Steenackers W, Cesarino I, Klíma P, Quareshy M, Vanholme R, Corneillie S, Kumpf RP, Van de Wouwer D, Ljung K, Goeminne G, Novák O, Zažímalová E, Napier R, Boerjan W, Vanholme B. The Allelochemical MDCA Inhibits Lignification and Affects Auxin Homeostasis. PLANT PHYSIOLOGY 2016; 172:874-888. [PMID: 27506238 PMCID: PMC5047068 DOI: 10.1104/pp.15.01972] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Accepted: 08/03/2016] [Indexed: 05/05/2023]
Abstract
The phenylpropanoid 3,4-(methylenedioxy)cinnamic acid (MDCA) is a plant-derived compound first extracted from roots of Asparagus officinalis and further characterized as an allelochemical. Later on, MDCA was identified as an efficient inhibitor of 4-COUMARATE-CoA LIGASE (4CL), a key enzyme of the general phenylpropanoid pathway. By blocking 4CL, MDCA affects the biosynthesis of many important metabolites, which might explain its phytotoxicity. To decipher the molecular basis of the allelochemical activity of MDCA, we evaluated the effect of this compound on Arabidopsis thaliana seedlings. Metabolic profiling revealed that MDCA is converted in planta into piperonylic acid (PA), an inhibitor of CINNAMATE-4-HYDROXYLASE (C4H), the enzyme directly upstream of 4CL. The inhibition of C4H was also reflected in the phenolic profile of MDCA-treated plants. Treatment of in vitro grown plants resulted in an inhibition of primary root growth and a proliferation of lateral and adventitious roots. These observed growth defects were not the consequence of lignin perturbation, but rather the result of disturbing auxin homeostasis. Based on DII-VENUS quantification and direct measurement of cellular auxin transport, we concluded that MDCA disturbs auxin gradients by interfering with auxin efflux. In addition, mass spectrometry was used to show that MDCA triggers auxin biosynthesis, conjugation, and catabolism. A similar shift in auxin homeostasis was found in the c4h mutant ref3-2, indicating that MDCA triggers a cross talk between the phenylpropanoid and auxin biosynthetic pathways independent from the observed auxin efflux inhibition. Altogether, our data provide, to our knowledge, a novel molecular explanation for the phytotoxic properties of MDCA.
Collapse
Affiliation(s)
- Ward Steenackers
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Igor Cesarino
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Petr Klíma
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Mussa Quareshy
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Ruben Vanholme
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Sander Corneillie
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Robert Peter Kumpf
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Dorien Van de Wouwer
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Karin Ljung
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Geert Goeminne
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Ondřej Novák
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Eva Zažímalová
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Richard Napier
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Wout Boerjan
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| | - Bartel Vanholme
- Department of Plant Systems Biology, VIB, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Gent, Belgium (W.S., I.C., R.V., S.C., R.P.K., D.V.d.W., G.G., W.B., B.V.);Department of Botany, Institute of Biosciences, University of São Paulo, 05508-090 Butantã, São Paulo, Brazil (I.C.);Institute of Experimental Botany, the Czech Academy of Sciences, 16502 Prague, the Czech Republic (P.K., E.Z.);School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom (M.Q., R.N.);Umeå Plant Science Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, SE-901 83 Umeå, Sweden (K.L., O.N.); andLaboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany CAS and Faculty of Science of Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic (O.N.)
| |
Collapse
|
18
|
|
19
|
Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, Soule CK, Alexander B, Li A, Montgomery P, Kotz JD, Hon CSY, Munoz B, Liefeld T, Dančík V, Haber DA, Clish CB, Bittker JA, Palmer M, Wagner BK, Clemons PA, Shamji AF, Schreiber SL. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol 2015; 12:109-16. [PMID: 26656090 PMCID: PMC4718762 DOI: 10.1038/nchembio.1986] [Citation(s) in RCA: 509] [Impact Index Per Article: 56.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Accepted: 11/09/2015] [Indexed: 12/18/2022]
Abstract
Changes in cellular gene expression in response to small-molecule or genetic perturbations have yielded signatures that can connect unknown mechanisms of action (MoA) to ones previously established. We hypothesized that differential basal gene expression could be correlated with patterns of small-molecule sensitivity across many cell lines to illuminate the actions of compounds whose MoA are unknown. To test this idea, we correlated the sensitivity patterns of 481 compounds with ∼19,000 basal transcript levels across 823 different human cancer cell lines and identified selective outlier transcripts. This process yielded many novel mechanistic insights, including the identification of activation mechanisms, cellular transporters and direct protein targets. We found that ML239, originally identified in a phenotypic screen for selective cytotoxicity in breast cancer stem-like cells, most likely acts through activation of fatty acid desaturase 2 (FADS2). These data and analytical tools are available to the research community through the Cancer Therapeutics Response Portal.
Collapse
Affiliation(s)
| | - Brinton Seashore-Ludlow
- Broad Institute, Cambridge, Massachusetts, USA.,Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; Novartis Institutes for Biomedical Research, Emeryville, California, USA; Pfizer, Cambridge, Massachusetts, USA; University of California San Diego School of Medicine, La Jolla, California, USA; ImmunoGen, Waltham, Massachusetts, USA
| | - Jaime H Cheah
- Broad Institute, Cambridge, Massachusetts, USA.,Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; Novartis Institutes for Biomedical Research, Emeryville, California, USA; Pfizer, Cambridge, Massachusetts, USA; University of California San Diego School of Medicine, La Jolla, California, USA; ImmunoGen, Waltham, Massachusetts, USA
| | - Drew J Adams
- Broad Institute, Cambridge, Massachusetts, USA.,Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; Novartis Institutes for Biomedical Research, Emeryville, California, USA; Pfizer, Cambridge, Massachusetts, USA; University of California San Diego School of Medicine, La Jolla, California, USA; ImmunoGen, Waltham, Massachusetts, USA
| | - Edmund V Price
- Broad Institute, Cambridge, Massachusetts, USA.,Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; Novartis Institutes for Biomedical Research, Emeryville, California, USA; Pfizer, Cambridge, Massachusetts, USA; University of California San Diego School of Medicine, La Jolla, California, USA; ImmunoGen, Waltham, Massachusetts, USA
| | | | - Sarah Javaid
- Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts, USA
| | | | | | - Nicole E Bodycombe
- Broad Institute, Cambridge, Massachusetts, USA.,Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; Novartis Institutes for Biomedical Research, Emeryville, California, USA; Pfizer, Cambridge, Massachusetts, USA; University of California San Diego School of Medicine, La Jolla, California, USA; ImmunoGen, Waltham, Massachusetts, USA
| | - Christian K Soule
- Broad Institute, Cambridge, Massachusetts, USA.,Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; Novartis Institutes for Biomedical Research, Emeryville, California, USA; Pfizer, Cambridge, Massachusetts, USA; University of California San Diego School of Medicine, La Jolla, California, USA; ImmunoGen, Waltham, Massachusetts, USA
| | | | - Ava Li
- Broad Institute, Cambridge, Massachusetts, USA
| | | | | | | | | | - Ted Liefeld
- Broad Institute, Cambridge, Massachusetts, USA.,Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; Novartis Institutes for Biomedical Research, Emeryville, California, USA; Pfizer, Cambridge, Massachusetts, USA; University of California San Diego School of Medicine, La Jolla, California, USA; ImmunoGen, Waltham, Massachusetts, USA
| | | | - Daniel A Haber
- Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts, USA
| | | | | | - Michelle Palmer
- Broad Institute, Cambridge, Massachusetts, USA.,Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; Novartis Institutes for Biomedical Research, Emeryville, California, USA; Pfizer, Cambridge, Massachusetts, USA; University of California San Diego School of Medicine, La Jolla, California, USA; ImmunoGen, Waltham, Massachusetts, USA
| | | | | | | | | |
Collapse
|
20
|
Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells. Eur J Pharmacol 2015. [DOI: 10.1016/j.ejphar.2015.07.047] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
21
|
Ducassou L, Jonasson G, Dhers L, Pietrancosta N, Ramassamy B, Xu-Li Y, Loriot MA, Beaune P, Bertho G, Lombard M, Mansuy D, André F, Boucher JL. Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies. Biochim Biophys Acta Gen Subj 2015; 1850:1426-37. [DOI: 10.1016/j.bbagen.2015.03.014] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2015] [Revised: 03/23/2015] [Accepted: 03/30/2015] [Indexed: 11/17/2022]
|
22
|
Khade RL, Zhang Y. Catalytic and Biocatalytic Iron Porphyrin Carbene Formation: Effects of Binding Mode, Carbene Substituent, Porphyrin Substituent, and Protein Axial Ligand. J Am Chem Soc 2015; 137:7560-3. [PMID: 26067900 PMCID: PMC4482416 DOI: 10.1021/jacs.5b03437] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Indexed: 11/28/2022]
Abstract
Iron porphyrin carbenes (IPCs) are important intermediates in various chemical reactions catalyzed by iron porphyrins and engineered heme proteins, as well as in the metabolism of various xenobiotics by cytochrome P450. However, there are no prior theoretical reports to help understand their formation mechanisms and identify key information governing the binding mode, formation feasibility, and stability/reactivity. A systematic quantum chemical study was performed to investigate the effects of carbene substituent, porphyrin substituent, and axial ligand on IPC formation pathways. Results not only are consistent with available experimental data but also provide a number of unprecedented insights into electronic, steric, and H-bonding effects of various structural factors on IPC formation mechanisms. These results shall facilitate research on IPC and related systems for sustainable chemical catalysis and biocatalysis.
Collapse
Affiliation(s)
- Rahul L Khade
- Department of Chemistry, Chemical Biology, and Biomedical Engineering, Stevens Institute of Technology, Castle Point on Hudson, Hoboken, New Jersey 07030, United States
| | - Yong Zhang
- Department of Chemistry, Chemical Biology, and Biomedical Engineering, Stevens Institute of Technology, Castle Point on Hudson, Hoboken, New Jersey 07030, United States
| |
Collapse
|
23
|
Chen C, Wang DW. Cytochrome P450-CYP2 Family-Epoxygenase Role in Inflammation and Cancer. CYTOCHROME P450 FUNCTION AND PHARMACOLOGICAL ROLES IN INFLAMMATION AND CANCER 2015; 74:193-221. [DOI: 10.1016/bs.apha.2015.04.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
24
|
Meling DD, McDougle DR, Das A. CYP2J2 epoxygenase membrane anchor plays an important role in facilitating electron transfer from CPR. J Inorg Biochem 2014; 142:47-53. [PMID: 25450017 DOI: 10.1016/j.jinorgbio.2014.09.016] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2014] [Revised: 09/25/2014] [Accepted: 09/25/2014] [Indexed: 01/07/2023]
Abstract
CYP2J2 epoxygenase is a membrane-bound cytochrome P450 primarily expressed in the heart and plays a significant role in cardiovascular diseases. The interactions of CYP2J2 with its redox partner, cytochrome P450 reductase (CPR), and with its substrates are quite complex and can have a significant effect on the kinetics of substrate metabolism. Here we show that the N-terminus of CYP2J2 plays an important role in the formation of CYP-CPR complex for subsequent electron transfer. We demonstrate that when CYP2J2-CPR are pre-incubated before the onset of reduction, the kinetics of reduction is triphasic and is of a similar order of magnitude to previously reported rates in other cytochrome P450 systems. However, when CYP2J2 and CPR form a complex during the time course of the experiment the kinetics of the fastest phase for N-terminus containing full-length CYP2J2 is 200 times faster than the kinetics of reduction of N-terminally truncated CYP2J2. Hence, we show that the N-terminus of CYP2J2 is very important to form a productive CYP-CPR complex to facilitate electron transfer.
Collapse
Affiliation(s)
- Daryl D Meling
- Department of Biochemistry, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States
| | - Daniel R McDougle
- Department of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States; Medical Scholars Program, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States
| | - Aditi Das
- Department of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States; Department of Biochemistry, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States; Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States; Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL 61801, United States.
| |
Collapse
|
25
|
Potential of decursin to inhibit the human cytochrome P450 2J2 isoform. Food Chem Toxicol 2014; 70:94-9. [DOI: 10.1016/j.fct.2014.04.020] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2013] [Revised: 04/07/2014] [Accepted: 04/11/2014] [Indexed: 11/20/2022]
|
26
|
Lu J, Qin X, Liu M, Wang X. A note on CYP2J2-mediated terfenadine hydroxylation in human liver microsomes. Food Chem Toxicol 2014; 71:284-5. [PMID: 24997310 DOI: 10.1016/j.fct.2014.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Jian Lu
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
| | - Xuan Qin
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
| | - Mingyao Liu
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China; Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, TX, United States
| | - Xin Wang
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
| |
Collapse
|
27
|
Kaspera R, Kirby BJ, Sahele T, Collier AC, Kharasch ED, Unadkat JD, Totah RA. Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochem Pharmacol 2014; 91:109-18. [PMID: 24973543 DOI: 10.1016/j.bcp.2014.06.020] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Revised: 06/17/2014] [Accepted: 06/18/2014] [Indexed: 10/25/2022]
Abstract
Ritonavir, an HIV protease inhibitor, is successfully used for the prevention and treatment of HIV infections. Ritonavir pharmacokinetics are complicated by inhibition, induction and pharmacogenetics of cytochrome P450 (CYP) enzymes mediating its clearance. This investigation revealed that CYP2J2, along with CYP3A4/5 and CYP2D6, efficiently metabolizes ritonavir, and to a CYP2J2-specific (minor) metabolite. Chemical inhibition of ritonavir metabolism, clearance, KI/kinact and abundance of CYP2J2 in liver microsomes were evaluated and then applied to an in vitro-in vivo static scaling model to estimate the contribution of each isozyme, as a function of CYP abundance, activity, and genotype. Disposition of the CYP2J2-specific metabolite was also evaluated in vivo. In plasma, metabolite abundance was well above previously reported levels with circulating concentrations measured at 2 μM for the main hydroxylisopropyl metabolite. Ritonavir and metabolite plasma profiles were simulated using Simcyp(®). A modest (2-6%) contribution of CYP2J2 to ritonavir clearance is predicted which increases to more than 20% in subjects carrying CYP2D6 poor metabolizer polymorphisms and CYP3A4 irreversible inhibition. These results indicate that minor drug metabolizing enzymes could become quantitatively important in RTV clearance if main metabolic pathways are impeded.
Collapse
Affiliation(s)
- Rüdiger Kaspera
- Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195-7610, USA.
| | - Brian J Kirby
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195-7630, USA.
| | - Tariku Sahele
- Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195-7610, USA.
| | - Ann C Collier
- Department of Medicine, University of Washington, Box 359929, Seattle, WA 98195-9929, USA.
| | - Evan D Kharasch
- Department of Anesthesiology, School of Medicine, Washington University, 660 South Euclid Avenue, Campus Box 8054, St. Louis, MO 63110, USA.
| | - Jashvant D Unadkat
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195-7630, USA.
| | - Rheem A Totah
- Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195-7610, USA.
| |
Collapse
|
28
|
Khade RL, Fan W, Ling Y, Yang L, Oldfield E, Zhang Y. Iron porphyrin carbenes as catalytic intermediates: structures, Mössbauer and NMR spectroscopic properties, and bonding. Angew Chem Int Ed Engl 2014; 53:7574-8. [PMID: 24910004 DOI: 10.1002/anie.201402472] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2014] [Revised: 04/08/2014] [Indexed: 11/07/2022]
Abstract
Iron porphyrin carbenes (IPCs) are thought to be intermediates involved in the metabolism of various xenobiotics by cytochrome P450, as well as in chemical reactions catalyzed by metalloporphyrins and engineered P450s. While early work proposed IPCs to contain Fe(II), more recent work invokes a double-bond description of the iron-carbon bond, similar to that found in Fe(IV) porphyrin oxenes. Reported herein is the first quantum chemical investigation of IPC Mössbauer and NMR spectroscopic properties, as well as their electronic structures, together with comparisons to ferrous heme proteins and an Fe(IV) oxene model. The results provide the first accurate predictions of the experimental spectroscopic observables as well as the first theoretical explanation of their electrophilic nature, as deduced from experiment. The preferred resonance structure is Fe(II)←{:C(X)Y}(0) and not Fe(IV)={C(X)Y}(2-), a result that will facilitate research on IPC reactivities in various chemical and biochemical systems.
Collapse
Affiliation(s)
- Rahul L Khade
- Department of Chemistry, Chemical Biology, and Biomedical, Engineering, Stevens Institute of Technology, Castle Point on Hudson, Hoboken, NJ 07030 (USA)
| | | | | | | | | | | |
Collapse
|
29
|
Khade RL, Fan W, Ling Y, Yang L, Oldfield E, Zhang Y. Iron Porphyrin Carbenes as Catalytic Intermediates: Structures, Mössbauer and NMR Spectroscopic Properties, and Bonding. Angew Chem Int Ed Engl 2014. [DOI: 10.1002/ange.201402472] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
30
|
Xu M, Ju W, Hao H, Wang G, Li P. Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance. Drug Metab Rev 2014; 45:311-52. [PMID: 23865864 DOI: 10.3109/03602532.2013.806537] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Cytochrome P450 2J2 (CYP2J2) is an enzyme mainly found in human extrahepatic tissues, with predominant expression in the cardiovascular systems and lower levels in the intestine, kidney, lung, pancreas, brain, liver, etc. During the past 15 years, CYP2J2 has attracted much attention for its epoxygenase activity in arachidonic acid (AA) metabolism. It converts AA to four epoxyeicosatrienoic acids (EETs) that have various biological effects, especially in the cardiovascular systems. In recent publications, CYP2J2 is shown highly expressed in various human tumor cells, and its EET metabolites are demonstrated to implicate in the pathologic development of human cancers. CYP2J2 is also a human CYP that involved in phase I xenobiotics metabolism. Antihistamine drugs and many other compounds were identified as the substrates of CYP2J2, and studies have demonstrated that these substrates have a broad structural diversity. CYP2J2 is found not readily induced by known P450 inducers; however, its expression could be regulated in some pathological conditions, might through the activator protein-1(AP-1), the AP-1-like element and microRNA let-7b. Several genetic mutations in the CYP2J2 gene have been identified in humans, and some of them have been shown to have potential associations with some diseases. With the increasing awareness of its roles in cancer disease and drug metabolism, studies about CYP2J2 are still going on, and various inhibitors of CYP2J2 have been determined. Further studies are needed to delineate the roles of CYP2J2 in disease pathology, drug development and clinical practice.
Collapse
Affiliation(s)
- Meijuan Xu
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
| | | | | | | | | |
Collapse
|
31
|
Bystrom J, Thomson SJ, Johansson J, Edin ML, Zeldin DC, Gilroy DW, Smith AM, Bishop-Bailey D. Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease? PLoS One 2013; 8:e75107. [PMID: 24058654 PMCID: PMC3772848 DOI: 10.1371/journal.pone.0075107] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2013] [Accepted: 08/09/2013] [Indexed: 12/19/2022] Open
Abstract
The epoxygenase CYP2J2 has an emerging role in inflammation and vascular biology. The role of CYP2J2 in phagocytosis is not known and its regulation in human inflammatory diseases is poorly understood. Here we investigated the role of CYP2J2 in bacterial phagocytosis and its expression in monocytes from healthy controls and Crohns disease patients. CYP2J2 is anti-inflammatory in human peripheral blood monocytes. Bacterial LPS induced CYP2J2 mRNA and protein. The CYP2J2 arachidonic acid products 11,12-EET and 14,15-EET inhibited LPS induced TNFα release. THP-1 monocytes were transformed into macrophages by 48h incubation with phorbol 12-myristate 13-acetate. Epoxygenase inhibition using a non-selective inhibitor SKF525A or a selective CYP2J2 inhibitor Compound 4, inhibited E. coli particle phagocytosis, which could be specifically reversed by 11,12-EET. Moreover, epoxygenase inhibition reduced the expression of phagocytosis receptors CD11b and CD68. CD11b also mediates L. monocytogenes phagocytosis. Similar, to E. coli bioparticle phagocytosis, epoxygenase inhibition also reduced intracellular levels of L. monocytogenes, which could be reversed by co-incubation with 11,12-EET. Disrupted bacterial clearance is a hallmark of Crohn’s disease. Unlike macrophages from control donors, macrophages from Crohn’s disease patients showed no induction of CYP2J2 in response to E. coli. These results demonstrate that CYP2J2 mediates bacterial phagocytosis in macrophages, and implicates a defect in the CYP2J2 pathway may regulate bacterial clearance in Crohn’s disease.
Collapse
MESH Headings
- 8,11,14-Eicosatrienoic Acid/analogs & derivatives
- 8,11,14-Eicosatrienoic Acid/metabolism
- Antigens, CD/biosynthesis
- Antigens, CD/genetics
- Antigens, Differentiation, Myelomonocytic/biosynthesis
- Antigens, Differentiation, Myelomonocytic/genetics
- CD11b Antigen/biosynthesis
- CD11b Antigen/genetics
- Cell Line
- Crohn Disease/genetics
- Crohn Disease/metabolism
- Crohn Disease/microbiology
- Crohn Disease/pathology
- Cytochrome P-450 CYP2J2
- Cytochrome P-450 Enzyme System/biosynthesis
- Cytochrome P-450 Enzyme System/genetics
- Enzyme Induction/drug effects
- Escherichia coli/metabolism
- Female
- Humans
- Lipopolysaccharides/pharmacology
- Macrophages/enzymology
- Macrophages/microbiology
- Macrophages/pathology
- Male
- Monocytes/enzymology
- Monocytes/microbiology
- Monocytes/pathology
- Phagocytosis
Collapse
Affiliation(s)
- Jonas Bystrom
- William Harvey Research Institute, Queen Mary University, London, United Kingdom
| | - Scott J. Thomson
- Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom
| | | | - Matthew L. Edin
- Division of Intramural Research, National Institute of Environmental Health Sciences/National Institutes of Health, Research Triangle Park, North Carolina, United States of America
| | - Darryl C. Zeldin
- Division of Intramural Research, National Institute of Environmental Health Sciences/National Institutes of Health, Research Triangle Park, North Carolina, United States of America
| | - Derek W. Gilroy
- Department of Medicine, University College London, London, United Kingdom
| | - Andrew M. Smith
- Department of Medicine, University College London, London, United Kingdom
| | - David Bishop-Bailey
- Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom
- * E-mail:
| |
Collapse
|
32
|
Evangelista EA, Kaspera R, Mokadam NA, Jones JP, Totah RA. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes. Drug Metab Dispos 2013; 41:2087-94. [PMID: 24021950 DOI: 10.1124/dmd.113.053389] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Cytochrome P450 2J2 plays a significant role in the epoxidation of arachidonic acid to signaling molecules important in cardiovascular events. CYP2J2 also contributes to drug metabolism and is responsible for the intestinal clearance of ebastine. However, the interaction between arachidonic acid metabolism and drug metabolism in cardiac tissue, the main expression site of CYP2J2, has not been examined. Here we investigate an adult-derived human primary cardiac cell line as a suitable model to study metabolic drug interactions (inhibition and induction) of CYP2J2 in cardiac tissue. The primary human cardiomyocyte cell line demonstrated similar mRNA-expression profiles of P450 enzymes to adult human ventricular tissue. CYP2J2 was the dominant isozyme with minor contributions from CYP2D6 and CYP2E1. Both terfenadine and astemizole oxidation were observed in this cell line, whereas midazolam was not metabolized suggesting lack of CYP3A activity. Compared with recombinant CYP2J2, terfenadine was hydroxylated in cardiomyocytes at a similar K(m) value of 1.5 μM. The V(max) of terfenadine hydroxylation in recombinant enzyme was found to be 29.4 pmol/pmol P450 per minute and in the cells 6.0 pmol/pmol P450 per minute. CYP2J2 activity in the cell line was inhibited by danazol, astemizole, and ketoconazole in submicromolar range, but also by xenobiotics known to cause cardiac adverse effects. Of the 14 compounds tested for CYP2J2 induction, only rosiglitazone increased mRNA expression, by 1.8-fold. This cell model can be a useful in vitro model to investigate the role of CYP2J2-mediated drug metabolism, arachidonic acid metabolism, and their association to drug induced cardiotoxicity.
Collapse
Affiliation(s)
- Eric A Evangelista
- Department of Medicinal Chemistry (E.A.E., R.K., J.P.J., R.A.T.) and Division of Cardiothoracic Surgery, University of Washington, Seattle, Washington (N.A.M.)
| | | | | | | | | |
Collapse
|
33
|
Askari A, Thomson SJ, Edin ML, Zeldin DC, Bishop-Bailey D. Roles of the epoxygenase CYP2J2 in the endothelium. Prostaglandins Other Lipid Mediat 2013; 107:56-63. [PMID: 23474289 DOI: 10.1016/j.prostaglandins.2013.02.003] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2012] [Revised: 02/21/2013] [Accepted: 02/25/2013] [Indexed: 12/19/2022]
Abstract
Cytochrome p450 (CYP)2J2 is an epoxygenase enzyme that metabolises arachidonic acid to epoxyeicosatrienoic acids (EETs). EETs are inactivated by soluble epoxide hydrolase (sEH), which converts them in to their corresponding dihydroxyeicosatrienoic acids (DHETs). CYP2J2 is highly expressed in cardiovascular tissue including the heart and vascular endothelial cells. CYP2J2 and the EETs it produces have been shown to have a diverse range of effects on the vasculature, including the regulation of inflammation, vascular tone, cellular proliferation, angiogenesis, and metabolism. This review will examine these established and emerging roles of CYP2J2 in the biology of vascular endothelial cells.
Collapse
Affiliation(s)
- Ara Askari
- Translational Medicine & Therapeutics, William Harvey Research Institute, Barts & the London, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
| | | | | | | | | |
Collapse
|
34
|
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138:103-41. [PMID: 23333322 DOI: 10.1016/j.pharmthera.2012.12.007] [Citation(s) in RCA: 2488] [Impact Index Per Article: 226.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2012] [Accepted: 12/27/2012] [Indexed: 02/06/2023]
Abstract
Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging to the CYP1, 2, and 3 families, are responsible for the biotransformation of most foreign substances including 70-80% of all drugs in clinical use. The highest expressed forms in liver are CYPs 3A4, 2C9, 2C8, 2E1, and 1A2, while 2A6, 2D6, 2B6, 2C19 and 3A5 are less abundant and CYPs 2J2, 1A1, and 1B1 are mainly expressed extrahepatically. Expression of each CYP is influenced by a unique combination of mechanisms and factors including genetic polymorphisms, induction by xenobiotics, regulation by cytokines, hormones and during disease states, as well as sex, age, and others. Multiallelic genetic polymorphisms, which strongly depend on ethnicity, play a major role for the function of CYPs 2D6, 2C19, 2C9, 2B6, 3A5 and 2A6, and lead to distinct pharmacogenetic phenotypes termed as poor, intermediate, extensive, and ultrarapid metabolizers. For these CYPs, the evidence for clinical significance regarding adverse drug reactions (ADRs), drug efficacy and dose requirement is rapidly growing. Polymorphisms in CYPs 1A1, 1A2, 2C8, 2E1, 2J2, and 3A4 are generally less predictive, but new data on CYP3A4 show that predictive variants exist and that additional variants in regulatory genes or in NADPH:cytochrome P450 oxidoreductase (POR) can have an influence. Here we review the recent progress on drug metabolism activity profiles, interindividual variability and regulation of expression, and the functional and clinical impact of genetic variation in drug metabolizing P450s.
Collapse
|
35
|
Ren S, Zeng J, Mei Y, Zhang JZH, Yan SF, Fei J, Chen L. Discovery and Characterization of Novel, Potent, and Selective Cytochrome P450 2J2 Inhibitors. Drug Metab Dispos 2012; 41:60-71. [DOI: 10.1124/dmd.112.048264] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
36
|
A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol Ther 2012; 134:82-106. [DOI: 10.1016/j.pharmthera.2012.01.001] [Citation(s) in RCA: 276] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2011] [Accepted: 12/22/2011] [Indexed: 01/10/2023]
|
37
|
Lee CA, Jones JP, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos 2012; 40:943-51. [PMID: 22328583 DOI: 10.1124/dmd.111.043505] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
CYP2J2, an arachidonic acid epoxygenase, is recognized for its role in the first-pass metabolism of astemizole and ebastine. To fully assess the role of CYP2J2 in drug metabolism, a selective substrate and potent specific chemical inhibitor are essential. In this study, we report amiodarone 4-hydoxylation as a specific CYP2J2-catalyzed reaction with no CYP3A4, or other drug-metabolizing enzyme, involvement. Amiodarone 4-hydroxylation enabled the determination of liver relative activity factor and intersystem extrapolation factor for CYP2J2. Amiodarone 4-hydroxylation correlated with astemizole O-demethylation but not with CYP2J2 protein content in a sample of human liver microsomes. To identify a specific CYP2J2 inhibitor, 138 drugs were screened using terfenadine and astemizole as probe substrates with recombinant CYP2J2. Forty-two drugs inhibited CYP2J2 activity by ≥50% at 30 μM, but inhibition was substrate-dependent. Of these, danazol was a potent inhibitor of both hydroxylation of terfenadine (IC(50) = 77 nM) and O-demethylation of astemizole (K(i) = 20 nM), and inhibition was mostly competitive. Danazol inhibited CYP2C9, CYP2C8, and CYP2D6 with IC(50) values of 1.44, 1.95, and 2.74 μM, respectively. Amiodarone or astemizole were included in a seven-probe cocktail for cytochrome P450 (P450) drug-interaction screening potential, and astemizole demonstrated a better profile because it did not appreciably interact with other P450 probes. Thus, danazol, amiodarone, and astemizole will facilitate the ability to determine the metabolic role of CYP2J2 in hepatic and extrahepatic tissues.
Collapse
Affiliation(s)
- Caroline A Lee
- Department of Drug Metabolism, Pfizer Global Research, La Jolla, California, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Weiss M. Functional characterization of drug uptake and metabolism in the heart. Expert Opin Drug Metab Toxicol 2011; 7:1295-306. [DOI: 10.1517/17425255.2011.614233] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
39
|
Tam TW, Liu R, Arnason JT, Krantis A, Staines WA, Haddad PS, Foster BC. Cree antidiabetic plant extracts display mechanism-based inactivation of CYP3A4. Can J Physiol Pharmacol 2011; 89:13-23. [DOI: 10.1139/y10-104] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Seventeen Cree antidiabetic medicinal plants were studied to determine their potential to inhibit cytochrome P450 3A4 (CYP3A4) through mechanism-based inactivation (MBI). The ethanolic extracts of the medicinal plants were studied for their inhibition of CYP3A4 using the substrates testosterone and dibenzylfluorescein (DBF) in high pressure liquid chromatography (HPLC) and microtiter fluorometric assays, respectively. Using testosterone as a substrate, extracts of Alnus incana , Sarracenia purpurea , and Lycopodium clavatum were identified as potent CYP3A4 MBIs, while those from Abies balsamea , Picea mariana , Pinus banksiana , Rhododendron tomentosum , Kalmia angustifolia , and Picea glauca were identified as less potent inactivators. Not unexpectedly, the other substrate, DBF, showed a different profile of inhibition. Only A. balsamea was identified as a CYP3A4 MBI using DBF. Abies balsamea displayed both NADPH- and time-dependence of CYP3A4 inhibition using both substrates. Overall, several of the medicinal plants may markedly deplete CYP3A4 through MBI and, consequently, decrease the metabolism of CYP3A4 substrates including numerous medications used by diabetics.
Collapse
Affiliation(s)
- Teresa W. Tam
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Department of Pharmacology, Université de Montréal, Montréal, QC H3C 3J7, Canada
- Therapeutic Products Directorate, Health Canada, Ottawa, ON K1A 0K9, Canada
| | - Rui Liu
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Department of Pharmacology, Université de Montréal, Montréal, QC H3C 3J7, Canada
- Therapeutic Products Directorate, Health Canada, Ottawa, ON K1A 0K9, Canada
| | - John T. Arnason
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Department of Pharmacology, Université de Montréal, Montréal, QC H3C 3J7, Canada
- Therapeutic Products Directorate, Health Canada, Ottawa, ON K1A 0K9, Canada
| | - Anthony Krantis
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Department of Pharmacology, Université de Montréal, Montréal, QC H3C 3J7, Canada
- Therapeutic Products Directorate, Health Canada, Ottawa, ON K1A 0K9, Canada
| | - William A. Staines
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Department of Pharmacology, Université de Montréal, Montréal, QC H3C 3J7, Canada
- Therapeutic Products Directorate, Health Canada, Ottawa, ON K1A 0K9, Canada
| | - Pierre S. Haddad
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Department of Pharmacology, Université de Montréal, Montréal, QC H3C 3J7, Canada
- Therapeutic Products Directorate, Health Canada, Ottawa, ON K1A 0K9, Canada
| | - Brian C. Foster
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Department of Pharmacology, Université de Montréal, Montréal, QC H3C 3J7, Canada
- Therapeutic Products Directorate, Health Canada, Ottawa, ON K1A 0K9, Canada
| |
Collapse
|
40
|
Abstract
The cytochrome P450 monooxygenase system (CYP) is a multigene superfamily of heme-thiolate enzymes, which are important in the metabolism of foreign and endogenous compounds. Genetic variations, drug interactions, or pathophysiological factors can lead to reduced, absent, or increased enzymatic activity. This altered CYP activity greatly influences an individual's response to therapeutic treatment. What is not known is the impact of these changes on the many functional roles of CYP in physiological and pathophysiological processes of the heart. Many extrahepatic tissues, like heart, contain active P450 enzymes but lack information regarding their role in cellular injury or homeostasis. Much of our current knowledge about cardiac CYP has been limited to studies investigating the role of fatty acid metabolites in heart. Traditional risk factors including diabetes, smoking, and hypertension have well established links to cardiovascular disease. And new evidence strongly suggests exposure to chemicals and other environmental agents has a profound impact on the cardiovascular system. These risk factors can independently affect the expression and activity of CYP enzymes. Therefore, altered CYP activity is important from a detoxification as well as a bioactivation perspective. Considering CYP, interactions are greatly dependent on inherited differences or acquired changes in enzyme activity further research into their potential impact on pathogenesis, risk assessment, and therapy of heart disease is warranted. This review explores the expression of CYP isoforms, their functional roles, and the effects of genetic variation in the heart.
Collapse
Affiliation(s)
- Ketul R Chaudhary
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2N8, Canada
| | | | | |
Collapse
|
41
|
Chen C, Li G, Liao W, Wu J, Liu L, Ma D, Zhou J, Elbekai RH, Edin ML, Zeldin DC, Wang DW. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther 2009; 329:908-18. [PMID: 19289568 DOI: 10.1124/jpet.109.152017] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
The cytochrome P450 epoxygenase, CYP2J2, converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs). We found recently that this enzyme is dramatically up-regulated in a variety of established human carcinoma cell lines and in human cancerous tissue and promotes the neoplastic phenotype. In the present study, we tested the hypothesis that specific inhibitors of CYP2J2 related to the drug terfenadine are effective antitumor agents. Four of these inhibitors (compounds 4, 5, 11, and 26) were tested for effectiveness in vitro and in vivo. In Tca-8113 cells, the CYP2J2 inhibitors decreased EET production by approximately 60%, whereas they had no effect on CYP2J2 mRNA or protein expression. Compound 26 inhibited the proliferation of human tumor cells, reduced their ability to adhere, invade, and migrate, and attenuated activation of epithelial growth factor receptor signal and kinases and phosphatidylinositol 3 kinase/Akt pathways. Inhibition of CYP2J2 also significantly potentiated human tumor cell apoptosis and caused a corresponding increase in caspase-3 activity and change in expression of apoptosis-related proteins Bax and Bcl-2. In murine xenograft models using MDA-MB-435 cells, treatment with compound 26 significantly repressed tumor growth, decreased lung metastasis, and was associated with increased expression of the anticancer genes CD82 and nm23, without causing toxicity. These data suggest that CYP2J2 inhibitors hold significant promise for use in treatment of neoplastic diseases.
Collapse
Affiliation(s)
- Chen Chen
- Department Internal Medicine and the Institute of Hypertension, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
El Ouarradi A, Salard-Arnaud I, Buisson D. Biooxidation of methyl group: application to the preparation of alcohol and acid metabolites of terfenadine, ebastine and analogues. Tetrahedron 2008. [DOI: 10.1016/j.tet.2008.09.098] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
43
|
Lafite P, André F, Zeldin DC, Dansette PM, Mansuy D. Unusual regioselectivity and active site topology of human cytochrome P450 2J2. Biochemistry 2007; 46:10237-47. [PMID: 17705402 PMCID: PMC2377029 DOI: 10.1021/bi700876a] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The oxidation of six derivatives of terfenadone by recombinant human CYP2J2 (CYP = cytochrome P450) was studied by high-performance liquid chromatography coupled to mass spectrometry (MS) using tandem MS techniques and by 1H NMR spectroscopy. CYP2J2 exhibited a surprising regioselectivity in favor of the hydroxylation of the substrate terminal chain at the weakly reactive homobenzylic position. In contrast, hydroxylation of the same substrates by CYP3A4 mainly occurred on the most chemically reactive sites of the substrates (N-oxidation and benzylic hydroxylation). A 3D homology model of CYP2J2 was constructed using recently published structures of CYP2A6, CYP2B4, CYP2C8, CYP2C9, and CYP2D6 as templates. In contrast with other CYP2 structures, it revealed an active site cavity with a severely restricted access of substrates to the heme through a narrow hydrophobic channel. Dynamic docking of terfenadone derivatives in the CYP2J2 active site allowed one to interpret the unexpected regioselectivity of the hydroxylation of these substrates by CYP2J2, which is mainly based on this restricted access to the iron. The structural features that have been found to be important for recognition of substrates or inhibitors by CYP2J2 were also interpreted on the basis of CYP2J2-substrate interactions in this model.
Collapse
Affiliation(s)
- Pierre Lafite
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CNRS UMR 8601, Université Paris Descartes, 45 Rue des Saints Pères, 75270 Paris Cedex 06, France
| | | | | | | | | |
Collapse
|